SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Shavkunov Alexander S.) "

Sökning: WFRF:(Shavkunov Alexander S.)

  • Resultat 1-2 av 2
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Lichti, Cheryl F., et al. (författare)
  • Integrated Chromosome 19 Transcriptomic and Proteomic Data Sets Derived from Glioma Cancer Stem-Cell Lines
  • 2014
  • Ingår i: Journal of Proteome Research. - : American Chemical Society (ACS). - 1535-3893 .- 1535-3907. ; 13:1, s. 191-199
  • Tidskriftsartikel (refereegranskat)abstract
    • One subproject within the global Chromosome 19 Consortium is to define chromosome 19 gene and protein expression in glioma-derived cancer stem cells (GSCs). Chromosome 19 is notoriously linked to glioma by 1p/19q codeletions, and clinical tests are established to detect that specific aberration. GSCs are tumor-initiating cells and are hypothesized to provide a repository of cells in tumors that can self-replicate and be refractory to radiation and chemotherapeutic agents developed for the treatment of tumors. In this pilot study, we performed RNA-Seq, label-free quantitative protein measurements in six GSC lines, and targeted transcriptomic analysis using a chromosome 19-specific microarray in an additional six GSC lines. The data have been deposited to the ProteomeXchange with identifier PXD000563. Here we present insights into differences in GSC gene and protein expression, including the identification of proteins listed as having no or low evidence at the protein level in the Human Protein Atlas, as correlated to chromosome 19 and GSC subtype. Furthermore, the upregulation of proteins downstream of adenovirus-associated integration site 1 (AAVS1) in GSC11 in response to oncolytic adenovirus treatment was demonstrated. Taken together, our results may indicate new roles for chromosome 19, beyond the 1p/19q codeletion, in the future of personalized medicine for glioma patients.
  •  
2.
  • Végvári, Ákos, et al. (författare)
  • Localization of Tamoxifen in Human Breast Tumor by MALDI Mass Spectrometry Imaging
  • 2016
  • Ingår i: Clinical and Translational Medicine. - : Wiley. - 2001-1326. ; 5:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Tamoxifen is used in endocrine treatment of breast cancer to inhibit estrogen signaling. A set of strati‐ ed ER‐positive and ER‐negative tumor sections was subjected to manual deposition of tamoxifen solution in order to investigate its spatial distribution upon exposure to interaction within thin tissue sections. Methods: The localization of tamoxifen in tumor sections was assessed by matrix assisted laser deposition/ioniza‐ tion mass spectrometry imaging. The images of extracted ion maps were analyzed for comparison of signal intensity distributions. Results: The precursor ion of tamoxifen (m/z 372.233) displayed heterogeneous signal intensity distributions in his‐ tological compartments of tumor tissue sections. The levels of tamoxifen in tumor cells compared with stroma were higher in ER‐positive tissues, whereas ER‐negative tissue sections showed lower signal intensities in tumor cells. Conclusions: The experimental model was successfully applied on frozen tumor samples allowing for di erentiation between ER groups based on distribution of tamoxifen.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-2 av 2

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy